This is it? GSK rolls out a buzzy new R&D plan long on aspirations and short on performance goals
GlaxoSmithKline set out to kickstart some enthusiasm for its pipeline this morning. But CEO Emma Walmsley and her new R&D chief Hal Barron clearly have …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.